Known targets — ChEMBL curated mechanism
FGFR3FLT1FLT3FLT4KDRKITPDGFRAPDGFRB
The experimentally established mechanism targets of Dovitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB known ✓ | P09619 | 17/20 | 0.86 |
| ▸ | KDR known ✓ | P35968 | 17/20 | 0.86 |
| ▸ | FLT1 known ✓ | P17948 | 4/20 | 0.86 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.86 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.86 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.86 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 0.86 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.86 |
| ▸ | FGFR1 | P11362 | 19/20 | 0.86 |
| ▸ | LCK | P06239 | 2/20 | 0.86 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.86 |
| ▸ | PLK4 | O00444 | 1/20 | 0.86 |
| ▸ | STK25 | O00506 | 1/20 | 0.86 |
| ▸ | CIT | O14578 | 1/20 | 0.86 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.86 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.86 |
| ▸ | GAK | O14976 | 1/20 | 0.86 |
| ▸ | CHUK | O15111 | 1/20 | 0.86 |
| ▸ | MUSK | O15146 | 1/20 | 0.86 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dovitinib SCHEMBL29358063 | 1.00 | FGFR1 (0.86) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL29352167 | 1.00 | FGFR1 (0.86) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL29435017 | 0.99 | FGFR1 (0.84) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL253994 | 0.99 | FGFR1 (0.84) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL29351344 | 0.99 | FGFR1 (0.84) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL946022 | 0.94 | FGFR1 (0.75) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL28897930 | 0.94 | FGFR1 (0.75) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL945391 | 0.93 | FGFR1 (0.73) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL172687 | 0.93 | FGFR1 (1.00) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL29424010 | 0.93 | FGFR1 (1.00) | FGFR1PDGFRBKDRFLT1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221389-A1 | USE OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE IN THE TREATMENT OF CANCER IN MODERATE HEPATIC IMPAIRED PATIENTS | NOVARTIS AG (CH) | 2014-08-07 | — | — | US | claimed |
| EP-2755655-A1 | USE OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE IN THE TREATMENT OF CANCER IN MODERATE HEPATIC IMPAIRED PATIENTS | Novartis AG (CH) | 2014-07-23 | — | — | EP | claimed |
| WO-2013039764-A1 | USE OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE IN THE TREATMENT OF CANCER IN MODERATE HEPATIC IMPAIRED PATIENTS | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | claimed |
| CN-106943355-B | Pharmaceutical composition | 诺华股份有限公司 | 2020-09-01 | — | — | CN | disclosed |
| EP-2588086-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTATE MONOHYDRATE. | NOVARTIS AG (CH) | 2018-09-12 | — | — | EP | disclosed |
| US-9545402-B2 | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-y1)-1H-benzimidazol-2-y1]-1H-quinolin-2-one lactate monohydrate | NOVARTIS AG (CH) | 2017-01-17 | — | — | US | disclosed |
| EP-2270000-B1 | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts | NOVARTIS AG (CH) | 2015-07-29 | — | — | EP | disclosed |
| EP-2270000-B1 | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts | NOVARTIS AG (CH) | 2015-07-29 | — | — | EP | disclosed |
| US-8987448-B2 | Preparation of anhydrous and hydrated polymorphs 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-YL)-1H-benzimidazol-2-YL]-1H-quinolin-2-one-lactic acid salt | NOVARTIS AG (CH) | 2015-03-24 | — | — | US | disclosed |
| US-8987448-B2 | Preparation of anhydrous and hydrated polymorphs 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-YL)-1H-benzimidazol-2-YL]-1H-quinolin-2-one-lactic acid salt | NOVARTIS AG (CH) | 2015-03-24 | — | — | US | disclosed |
| EP-2772257-A1 | Formulations of quinolinones | Novartis AG (CH) | 2014-09-03 | — | — | EP | disclosed |
| EP-1957074-A2 | FORMULATIONS OF QUINOLINONES | Novartis AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| CN-101218228-A | Crystalline and other forms of 4-amino-5-fluoro-3- [ 6- (4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl ] -1H-quinolin-2-one lactate | NOVARTIS AG (CH) | 2008-07-09 | — | — | CN | disclosed |
| CN-101218228-A | Crystalline and other forms of 4-amino-5-fluoro-3- [ 6- (4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl ] -1H-quinolin-2-one lactate | NOVARTIS AG (CH) | 2008-07-09 | — | — | CN | disclosed |
| EP-1904480-A2 | CRYSTALLINE AND OTHER FORMS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTIC ACID SALTS | Novartis Pharma AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| EP-1904480-A2 | CRYSTALLINE AND OTHER FORMS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTIC ACID SALTS | Novartis Pharma AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007064719-A2 | FORMULATIONS OF QUINOLINONES | NOVARTIS AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| WO-2006127926-A3 | CRYSTALLINE AND OTHER FORMS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTIC ACID SALTS | NOVARTIS AG (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006127926-A2 | CRYSTALLINE AND OTHER FORMS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTIC ACID SALTS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006127926-A2 | CRYSTALLINE AND OTHER FORMS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTIC ACID SALTS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221389-A1 | USE OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE IN THE TREATMENT OF CANCER IN MODERATE HEPATIC IMPAIRED PATIENTS | SLC10A1, PYGL, GOT2 | PDGFRB 4780/4885KDR 4392/4885FLT1 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.